ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

Status:
Recruiting

Trial end date:
2022-03-25

Target enrollment:

Participant gender:

The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.

Phase 1

ERX Pharmaceuticals

Magnesium Hydroxide